Neuralgia Treatment Market, By Treatment (Drug Based and Surgery), By End Use, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4328
|
Published Date
August 2025
|
Pages
322
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Neuralgia Treatment Market size was valued at US$ 2,695.91 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.
Neuralgia treatment involves managing a medical condition characterized by chronic nerve pain, which can result from injury, infection, or other underlying health issues. The primary goals of treatment are to relieve symptoms, slow disease progression, and prevent complications. Globally, governments are recognizing the growing burden of chronic pain disorders like neuralgia; for example, the World Health Organization (WHO) estimates that chronic pain affects over 20% of the world’s population, prompting increased funding and initiatives aimed at improving pain management and access to effective treatments worldwide.
Neuralgia Treatment Market- Market Dynamics
Rising Prevalence of Chronic Diseases Drives Market Growth
The rising prevalence of chronic diseases, particularly diabetes, is expected to fuel growth in the neuralgia treatment market. Chronic diseases are long-lasting conditions that require ongoing medical care and often limit daily activities. Diabetes, a metabolic disorder characterized by elevated blood glucose levels, can lead to diabetic neuropathy—a type of nerve damage that neuralgia treatments aim to address. According to the World Health Organization, a United Nations specialized agency based in Switzerland, noncommunicable diseases (NCDs) or chronic diseases accounted for 41 million deaths globally in 2023, representing 74% of all deaths worldwide. This growing burden of chronic illnesses, such as diabetes, is driving increased demand for effective neuralgia treatments.
Neuralgia Treatment Market- Segmentation Analysis:
The Global Neuralgia Treatment Market is segmented on the basis of Treatment, End Use, and Region.
The market is segmented into two categories based on treatment type: Drug-Based and Surgery. The surgery segment is expected to dominate the market in 2025, largely driven by the increasing demand for precise, minimally invasive treatment options such as robotic radiosurgery. These advanced surgical techniques provide targeted pain relief, significantly reducing the reliance on traditional medications or more invasive procedures. Robotic radiosurgery, in particular, offers high accuracy while minimizing damage to surrounding healthy tissues, leading to improved patient outcomes and faster recovery times. This growing preference for less invasive treatments reflects a broader trend in healthcare toward safer, more effective alternatives. According to the U.S. Food and Drug Administration (FDA), the approval and adoption of robotic-assisted surgical devices have increased by over 25% in the last five years, underlining the accelerating shift toward innovative surgical treatments.
Based on end-use, the market is divided into Hospitals & Clinics, Ambulatory Surgery Centers, and Others. In 2025, the Hospitals and Clinics segment is projected to hold the largest revenue share, driven by the widespread adoption of advanced, non-invasive technologies within these healthcare settings. Hospitals and clinics are investing heavily in technologies that enable more precise, targeted treatments, which reduce the need for invasive procedures and lead to faster patient recovery with less discomfort. This enhances overall patient satisfaction and outcomes, encouraging further integration of such technologies. Data from the Centers for Medicare & Medicaid Services (CMS) shows that hospitals accounted for nearly 65% of all surgical procedures in 2024, highlighting their critical role in driving demand for advanced neuralgia treatment solutions.
Neuralgia Treatment Market- Geographical Insights
North America is expected to hold the largest share of the neuralgia treatment market in 2025, driven primarily by the increasing prevalence of chronic pain conditions such as painful diabetic neuropathy (PDN) among diabetic patients. This has spurred demand for effective, non-invasive treatment options. In January 2024, the U.S. FDA approved Neuralace Medical’s non-invasive Axon Therapy for PDN, marking a significant advancement in pain management for diabetics suffering from limb nerve pain. Axon Therapy uses low-voltage electrical pulses to stimulate nerves and reduce pain without the need for drugs or surgery, offering a safer and more accessible alternative for many patients with chronic neuropathic pain.
The Asia-Pacific neuralgia treatment market is projected to experience the fastest growth over the forecast period, driven by innovative treatment solutions gaining regulatory approvals that expand nerve repair surgery options. For example, regenerative medicine company Orthocell Ltd. received approval from Singapore’s Health Sciences Authority (HSA) for its Remplir collagen wraps, with sales starting in the first quarter of 2025. Prior to this, Remplir was distributed in Australia and New Zealand by Device Technologies, enhancing nerve repair outcomes in the region.
Neuralgia Treatment Market- Competitive Landscape:
The neuralgia treatment market is moderately competitive, led by pharmaceutical giants such as Pfizer, GlaxoSmithKline, Novartis, and Biogen, which dominate with anticonvulsants, antidepressants, and topical analgesics. Increasing collaborations and mergers are reshaping the landscape, exemplified by Globus Medical’s acquisition of Nevro to broaden its neuromodulation product portfolio. Additionally, regional players in Asia-Pacific are gaining traction due to improved healthcare access and the availability of more affordable therapies. Market dynamics are influenced by advancements in targeted drug therapies, minimally invasive pain management techniques, and personalized treatment approaches.
Recent Developments:
- In January 2024, Zydus Lifesciences received final FDA approval for its generic Gabapentin tablets for treating postherpetic neuralgia (PHN). The approval covers 300 mg and 600 mg once-daily doses of the medication, which helps alleviate pain following shingles.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEURALGIA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- GSK plc.
- Pfizer Inc.
- Biogen
- Zydus Group (Cadila Healthcare Limited)
- H. Lundbeck A/S
- Novartis AG
- Others
GLOBAL NEURALGIA TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032
- Drug Based
- Anticonvulsant Medicines
- Tricyclic Antidepressants
- Surgery
- Radiofrequency Thermal Lesioning
- Stereotactic Radiosurgery
- Microvascular Decompression
- Others
GLOBAL NEURALGIA TREATMENT MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032
- Hospital & Clinics
- Ambulatory Surgery Centers
- Others
GLOBAL NEURALGIA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Neuralgia Treatment Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Neuralgia Treatment Market Snippet by Treatment
2.1.2. Neuralgia Treatment Market Snippet by End Use
2.1.3. Neuralgia Treatment Market Snippet by Country
2.1.4. Neuralgia Treatment Market Snippet by Region
2.2. Competitive Insights
3. Neuralgia Treatment Key Market Trends
3.1. Neuralgia Treatment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Neuralgia Treatment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Neuralgia Treatment Market Opportunities
3.4. Neuralgia Treatment Market Future Trends
4. Neuralgia Treatment Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Neuralgia Treatment Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Neuralgia Treatment Market Landscape
6.1. Neuralgia Treatment Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Neuralgia Treatment Market – By Treatment
7.1. Overview
7.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
7.1.2. Drug Based
7.1.2.1. Anticonvulsant Medicines
7.1.2.2. Tricyclic Antidepressants
7.1.3. Surgery
7.1.3.1. Radiofrequency Thermal Lesioning
7.1.3.2. Stereotactic Radiosurgery
7.1.3.3. Microvascular Decompression
7.1.3.4. Others
8. Neuralgia Treatment Market – By End Use
8.1. Overview
8.1.1. Segment Share Analysis, By End Use, 2024 & 2032 (%)
8.1.2. Hospital & Clinics
8.1.3. Ambulatory Surgery Centers
8.1.4. Others
9. Neuralgia Treatment Market– By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
9.2. North America
9.2.1. Overview
9.2.2. Neuralgia Treatment Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.2.4. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.2.5. North America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.2.6. U.S.
9.2.6.1. Overview
9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.6.3. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.2.6.4. U.S. Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.2.7. Canada
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.7.3. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.2.7.4. Canada Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Neuralgia Treatment Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.5. Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3.6. Germany
9.3.6.1. Overview
9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.6.3. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.6.4. Germany Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3.7. UK
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.7.3. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.7.4. UK Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3.8. France
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.8.3. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.8.4. France Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3.9. Italy
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.9.3. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.9.4. Italy Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3.10. Spain
9.3.10.1. Overview
9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.10.3. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.10.4. Spain Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3.11. The Netherlands
9.3.11.1. Overview
9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.11.3. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.11.4. The Netherlands Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3.12. Sweden
9.3.12.1. Overview
9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.12.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.12.4. Sweden Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3.13. Russia
9.3.13.1. Overview
9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.13.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.13.4. Russia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3.14. Poland
9.3.14.1. Overview
9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.14.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.14.4. Poland Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3.15. Rest of Europe
9.3.15.1. Overview
9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.15.3. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.3.15.4. Rest of the Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Neuralgia Treatment Key Manufacturers in Asia Pacific
9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.4.4. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.4.5. APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4.6. China
9.4.6.1. Overview
9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.6.3. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.4.6.4. China Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4.7. India
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.7.3. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.4.7.4. India Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4.8. Japan
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.8.3. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.4.8.4. Japan Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4.9. South Korea
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.9.3. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.4.9.4. South Korea Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4.10. Australia
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.10.3. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.4.10.4. Australia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4.11. Indonesia
9.4.11.1. Overview
9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.11.3. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.4.11.4. Indonesia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4.12. Thailand
9.4.12.1. Overview
9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.12.3. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.4.12.4. Thailand Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4.13. Philippines
9.4.13.1. Overview
9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.13.3. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.4.13.4. Philippines Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4.14. Rest of APAC
9.4.14.1. Overview
9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.14.3. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.4.14.4. Rest of APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.5. Latin America (LATAM)
9.5.1. Overview
9.5.2. Neuralgia Treatment Key Manufacturers in Latin America
9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.5.4. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.5.5. LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.5.6. Brazil
9.5.6.1. Overview
9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.6.3. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.5.6.4. Brazil Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.5.7. Mexico
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.7.3. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.5.7.4. Mexico Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.5.8. Argentina
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.8.3. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.5.8.4. Argentina Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.5.9. Colombia
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.9.3. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.5.9.4. Colombia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.5.10. Rest of LATAM
9.5.10.1. Overview
9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.10.3. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.5.10.4. Rest of LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa (MEA)
9.6.1. Overview
9.6.2. Neuralgia Treatment Key Manufacturers in Middle East and Africa
9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.6.4. MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.6.5. MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.6.6. Saudi Arabia
9.6.6.1. Overview
9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.6.3. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.6.6.4. Saudi Arabia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.6.7. UAE
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.7.3. UAE Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.6.7.4. UAE Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.6.8. Israel
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.8.3. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.6.8.4. Israel Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.6.9. Turkey
9.6.9.1. Overview
9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.9.3. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.6.9.4. Turkey Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.6.10. Algeria
9.6.10.1. Overview
9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.10.3. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.6.10.4. Algeria Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.6.11. Egypt
9.6.11.1. Overview
9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.11.3. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.6.11.4. Egypt Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.6.12. Rest of MEA
9.6.12.1. Overview
9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.12.3. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
9.6.12.4. Rest of MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
10. Key Vendor Analysis- Neuralgia Treatment Industry
10.1. Competitive Benchmarking
10.1.1. Competitive Dashboard
10.1.2. Competitive Positioning
10.2. Company Profiles
10.2.1. GSK plc.
10.2.2. Pfizer Inc.
10.2.3. Biogen
10.2.4. Zydus Group (Cadila Healthcare Limited)
10.2.5. H. Lundbeck A/S
10.2.6. Novartis AG
10.2.7. Others
11. 360 Degree AnalystView
12. Appendix
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
